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Background/introduction
The demand for conservative treatments for uterine
fibroids has increased during the last decade, as more
women wish to retain their uterus and avoid invasive pro-
cedures. MRgFUS is a well established conservative tech-
nology for the treatment of uterine fibroids. The
procedure is offered as a clinical treatment option (not as
a part of clinical trials) at the Sheba Medical Center for
many years, and was mostly self-paid by the patients.
From November 2013, the procedure has been covered by
the HMOs as a part of the Israeli National Health Insur-
ance Law. The aim of the study was to assess how reim-
bursement affects the number of MRgFUS enrollments
and treatments in a single tertiary center.
Methods
A retrospective analysis of the number of patients attend-
ing MRgFUS clinics before (December 2012 to February
2013, period I) and after reimbursement (December 2013
to February 2014, period II). For statistical analysis Fisher
exact test was performed.
Results and conclusions
In period I, 15 women out of 20 (75%) fulfilled basic
MRgFUS criteria and were referred for MRI. Twelve MRI,
7 were found suitable and 3 were ultimately treated. In per-
iod II, 39 women out of 63 (61.9%) fulfilled basic MRgFUS
criteria and were referred for MRI. Thirty performed MRI,
12 were found suitable all underwent MRgFUS treatment.
The number of treated patients was significantly higher
following the reimbursement (p<0.001).
Conclusions: Reimbursement significantly increased
the number of patients who attended the MRgFUS
clinics and quadrupled the number of treatments.
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